Opus Genetics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Opus Genetics, Inc. stock issued during period, value, new issues for the quarter ending 2020-03-31 was $2.13M, a 71.86% decline year-over-year.
- Opus Genetics, Inc. stock issued during period, value, new issues for the quarter ending 2019-12-31 was $0.00.
- Opus Genetics, Inc. stock issued during period, value, new issues for the quarter ending 2019-09-30 was $0.00.
- Opus Genetics, Inc. stock issued during period, value, new issues for the quarter ending 2019-06-30 was $0.00.
- Opus Genetics, Inc. stock issued during period, value, new issues for fiscal 2024 was $6.96M.
- Opus Genetics, Inc. stock issued during period, value, new issues for fiscal 2020 was $2.13M, a 71.86% decline from fiscal 2019.
- Opus Genetics, Inc. stock issued during period, value, new issues for fiscal 2019 was $7.55M, a 9.91% increase from fiscal 2018.
- Opus Genetics, Inc. stock issued during period, value, new issues for fiscal 2018 was $6.87M, a 34.52% decline from fiscal 2017.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $6.96M 10-K · filed 2026-03-12 | |
| 2020-12-31 | $2.13M 10-K · filed 2022-03-24 | |
| 2020-03-31 | $2.13M 10-Q · filed 2021-11-12 | $2.13M derived: sum of 4 quarters · filed 2021-11-12 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $7.55M 10-K · filed 2020-02-21 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | |
| 2019-03-31 | $7.55M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $6.87M 10-K · filed 2020-02-21 | |
| 2017-12-31 | $10.50M 10-K · filed 2019-03-07 | |
| 2016-12-31 | $6.91M 10-K · filed 2018-03-09 | |
| 2015-12-31 | $4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $5.25M 10-K · filed 2018-03-09 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | |
| 2014-12-31 | $16.31M 10-K · filed 2017-02-24 | |
| 2013-12-31 | $8.63M 10-K · filed 2016-03-14 | |
| 2012-12-31 | $5.54M 10-K · filed 2014-03-21 | |
| 2011-12-31 | $11.12M 10-K · filed 2014-03-21 | |
| 2010-12-31 | $8.20M 10-K · filed 2014-03-21 | |
| 2009-12-31 | $10.00M 10-K · filed 2014-03-21 | |
| 2008-12-31 | $155.51K 10-K · filed 2014-03-21 | |
| 2007-12-31 | $1.14M 10-K · filed 2014-03-21 | |
| 2005-12-31 | $8.35M 10-K · filed 2014-03-21 | |
| 2004-12-31 | $1.80K 10-K · filed 2014-03-21 | |
| 2003-12-31 | $2.00M 10-K · filed 2014-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |